Literature DB >> 29978870

Why develop photoactivated chemotherapy?

Sylvestre Bonnet1.   

Abstract

Photoactivated chemotherapy is an approach where a biologically active compound is protected against interaction with the cell environment by a light-cleavable protecting group, and unprotected by light irradiation. As such, PACT represents a major scientific opportunity for developing new bioactive inorganic compounds. However, the societal impact of this approach will only take off if the PACT field is used to address real societal challenges, i.e., therapeutic questions that make sense in a clinical context, rather than purely chemical questions. In particular, I advocate here that the field has become mature enough to switch from a compound-based approach, where a particular cancer model is chosen only to demonstrate the utility of a compound, to a disease-based approach, where the question of which disease to cure comes first: which PACT compound should I make to solve that particular clinical problem? The advantages and disadvantages of PACT vs. other phototherapeutic techniques are discussed, and a roadmap towards real clinical applications of PACT is drawn.

Entities:  

Year:  2018        PMID: 29978870     DOI: 10.1039/c8dt01585f

Source DB:  PubMed          Journal:  Dalton Trans        ISSN: 1477-9226            Impact factor:   4.390


  37 in total

1.  Characterization and Biological Activity of a Hydrogen Sulfide-Releasing Red Light-Activated Ruthenium(II) Complex.

Authors:  Joshua J Woods; Jian Cao; Alexander R Lippert; Justin J Wilson
Journal:  J Am Chem Soc       Date:  2018-09-19       Impact factor: 15.419

2.  Strained, Photoejecting Ru(II) Complexes that are Cytotoxic Under Hypoxic Conditions.

Authors:  John Roque; Dmytro Havrylyuk; Patrick C Barrett; Tariq Sainuddin; Julia McCain; Katsuya Colón; William T Sparks; Evan Bradner; Susan Monro; David Heidary; Colin G Cameron; Edith C Glazer; Sherri A McFarland
Journal:  Photochem Photobiol       Date:  2019-12-06       Impact factor: 3.421

3.  Visible-to-NIR-Light Activated Release: From Small Molecules to Nanomaterials.

Authors:  Roy Weinstain; Tomáš Slanina; Dnyaneshwar Kand; Petr Klán
Journal:  Chem Rev       Date:  2020-10-30       Impact factor: 60.622

Review 4.  Critical discussion of the applications of metal complexes for 2-photon photodynamic therapy.

Authors:  Johannes Karges; Hui Chao; Gilles Gasser
Journal:  J Biol Inorg Chem       Date:  2020-11-04       Impact factor: 3.358

5.  The anti-cancer effect of series of strained photoactivatable Ru(II) polypyridyl complexes on non-small-cell lung cancer and triple negative breast cancer cells.

Authors:  Christelle Fayad; Hassib Audi; Rony S Khnayzer; Costantine F Daher
Journal:  J Biol Inorg Chem       Date:  2020-11-22       Impact factor: 3.358

6.  Synthesis and biological assessment of a ruthenium(II) cyclopentadienyl complex in breast cancer cells and on the development of zebrafish embryos.

Authors:  Golara Golbaghi; Irène Pitard; Matthieu Lucas; Mohammad Mehdi Haghdoost; Yossef López de Los Santos; Nicolas Doucet; Shunmoogum A Patten; J Thomas Sanderson; Annie Castonguay
Journal:  Eur J Med Chem       Date:  2020-01-03       Impact factor: 6.514

7.  Os(II) Oligothienyl Complexes as a Hypoxia-Active Photosensitizer Class for Photodynamic Therapy.

Authors:  John A Roque; Patrick C Barrett; Houston D Cole; Liubov M Lifshits; Evan Bradner; Ge Shi; David von Dohlen; Susy Kim; Nino Russo; Gagan Deep; Colin G Cameron; Marta E Alberto; Sherri A McFarland
Journal:  Inorg Chem       Date:  2020-10-30       Impact factor: 5.165

8.  Classification of Metal-based Drugs According to Their Mechanisms of Action.

Authors:  Eszter Boros; Paul J Dyson; Gilles Gasser
Journal:  Chem       Date:  2019-11-07       Impact factor: 22.804

9.  Bis[pyrrolyl Ru(ii)] triads: a new class of photosensitizers for metal-organic photodynamic therapy.

Authors:  Deborah A Smithen; Susan Monro; Mitch Pinto; John Roque; Roberto M Diaz-Rodriguez; Huimin Yin; Colin G Cameron; Alison Thompson; Sherri A McFarland
Journal:  Chem Sci       Date:  2020-10-06       Impact factor: 9.825

10.  Photoactivatable Cell-Selective Dinuclear trans-Diazidoplatinum(IV) Anticancer Prodrugs.

Authors:  Huayun Shi; Isolda Romero-Canelón; Monika Hreusova; Olga Novakova; V Venkatesh; Abraha Habtemariam; Guy J Clarkson; Ji-Inn Song; Viktor Brabec; Peter J Sadler
Journal:  Inorg Chem       Date:  2018-10-26       Impact factor: 5.165

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.